Before you sign a single agreement, two numbers decide whether a pharma franchise is worth it: what you put in, and what you keep on every box you sell. A PCD pharma franchise investment is rarely one big cheque — it is a stock deposit, a starter order, promotional material and your own working capital, spread over the first few months. The margin side is where most newcomers get confused, because the gap between the net rate you pay and the MRP printed on the pack is not all yours. This guide separates the two and shows, with real arithmetic, what actually lands in your pocket.
Key takeaways (TL;DR)
- A single-territory PCD start typically runs ₹25,000 to ₹1,00,000; wider rights push it to a lakh or two plus.
- Margin lives in the spread between the net rate you pay the company and the price your stockist or retailer pays — commonly 20% to 40%+.
- Learn four numbers and the rest is easy: net rate, PTS (price to stockist), PTR (price to retailer) and MRP.
- High-value forms like injectables, IV infusions and eye drops can carry different margin dynamics than fast-moving generic tablets.
- Your real return depends on monopoly rights, reorder cycles and how much margin you give away to push volume — not the headline MRP-to-net gap alone.
Where the money actually goes
People hear “franchise” and picture a franchise fee. In PCD (Propaganda Cum Distribution) pharma, there usually isn’t one in the retail-chain sense. What you commit is split across a few buckets, and most of it is recoverable stock rather than sunk cost.
| Cost head | Indicative range | Recoverable? |
|---|---|---|
| Opening stock / first order | ₹20,000 – ₹75,000 | Yes — you sell it on |
| Promotional inputs (visual aids, samples, MR bags, gifts) | ₹5,000 – ₹25,000 | Partly |
| Security / stock deposit (if asked) | ₹0 – ₹50,000 | Usually refundable |
| Drug License & GST setup | ₹5,000 – ₹15,000 | One-time |
| Working capital (credit you extend, travel) | Varies | Cycles back |
Read the ranges as a starting band, not a quote. A tablet-and-syrup range in one district sits at the low end; a portfolio that leans on injectables or ophthalmics, or covers a whole state, sits well above it. Confirm exact figures and any deposit terms in writing before you commit.
The four numbers that decide your margin
Every PCD price conversation comes down to four reference points. Get fluent in these and you can read any rate list in seconds.
| Term | What it means | Who pays it |
|---|---|---|
| Net rate | The billing price the company charges you, the franchise partner | You → company |
| PTS | Price To Stockist — what a stockist/distributor pays | Stockist → you |
| PTR | Price To Retailer — what the chemist pays | Retailer → stockist |
| MRP | Maximum Retail Price printed on the pack | Patient → chemist |
Your gross margin is the distance between your net rate and the price at which you onward-sell — PTS if you supply stockists, PTR if you supply chemists directly. The MRP matters because it sets the ceiling and the scheme structure, but you never pocket the full MRP-minus-net figure: the retailer and stockist each take a slice on the way down.
A worked example, rupee by rupee
Take one product — say a tablet pack with an MRP of ₹100. A typical “high-margin” PCD structure might look like this. Numbers are illustrative; your actual rate card will differ.
| Level | Price | Margin earned at this step |
|---|---|---|
| MRP (on pack) | ₹100.00 | — |
| PTR (retailer pays) | ₹80.00 | Chemist keeps ~20% |
| PTS (stockist pays you) | ₹71.00 | Stockist keeps ~10% |
| Your net rate (you pay company) | ₹42.50 | You keep ~₹28.50 per pack |
In this example you buy at ₹42.50 and bill the stockist at ₹71.00, so your gross margin is roughly 40% on net rate. Sell direct to retailers at PTR and the spread widens further — but you then carry the distribution work the stockist would have done. Note what eats into it: any promotional scheme (a 10+1 bonus offer effectively shaves your margin), GST handling, credit you extend, and field expenses. The headline “40% margin” is gross; your kept margin after schemes and costs is the number to plan around.
Why the dosage form changes the maths
Not every product behaves like a ₹100 tablet. The form you stock shifts both the investment and the margin profile, and this is where a portfolio’s mix really shows.
Fast-moving generic tablets and syrups
Low ticket size, high reorder frequency. Percentage margins look generous, but the rupee margin per pack is small, so volume is everything. These are your cash-flow workhorses.
Injectables, IV infusions and ophthalmics
Higher MRPs and a smaller field of suppliers mean the absolute rupee margin per unit can be more attractive, and competition on rate is often gentler than in commodity tablets. They demand more careful cold-chain and handling, and the per-order value is larger, so working capital per line item rises. For a partner who can service hospitals, nursing homes and specialist clinics, a sterile-and-ophthalmic-led range can lift average margin per invoice rather than chasing thin-margin volume alone.
Stretching your return: practical levers
- Lock genuine monopoly rights. A true single-party territory protects your price; overlapping franchisees trigger discounting that quietly erodes margin.
- Right-size the opening order. Over-ordering slow movers ties up capital; under-ordering your hero products costs you reorders. Match stock to local demand.
- Mix the basket. Pair high-turn tablets and syrups for cash flow with a few higher-value injectable or ophthalmic lines for margin per invoice.
- Treat schemes as a budget, not a reflex. Every bonus offer is margin given away — spend it on lines that genuinely need a push.
- Watch the reorder cycle, not the first order. The real profit in PCD is in repeat billing, so the company’s restocking speed and consistency matter as much as its rate card.
Biozia Lifesciences is a WHO-GMP and ISO-certified manufacturer based in Yamunanagar, Haryana, offering PCD pharma franchise and monopoly rights across 250+ formulations in nine dosage forms — including injections, IV infusions and eye drops that many franchise companies can’t supply. With transparent net rates, dependable pan-India restocking and a leadership team carrying 40+ years in pharma, the model is built for partners who want both fast-moving volume and higher-value lines under one roof.
Want a clear rate card and territory for your area? Enquire about a PCD franchise with Biozia Lifesciences →
Related guides
- How to Start a PCD Pharma Franchise in India
- Documents Required for a PCD Pharma Franchise
- Monopoly Rights in PCD Pharma Franchise
Frequently asked questions
How much do I need to start a PCD pharma franchise?
For a single territory, an indicative start sits between ₹25,000 and ₹1,00,000, most of it going into recoverable opening stock rather than a fee. Wider or multi-district rights, or a range built around injectables and ophthalmics, can run to a lakh or two and beyond. Treat any figure as indicative and confirm the exact terms in writing.
What is the difference between net rate, PTS, PTR and MRP?
Net rate is what the company bills you. PTS is the price a stockist pays you, PTR is what a retailer pays the stockist, and MRP is the printed ceiling the patient pays. Your margin is the gap between your net rate and the level at which you sell on.
What profit margin can I realistically keep?
Gross margins of 20% to 40%-plus on net rate are common, but that is before promotional schemes, GST handling, credit and field costs. Plan around your kept margin after those deductions, not the headline figure.
Do injectables and eye drops earn more than tablets?
Often the rupee margin per unit is larger and rate competition gentler, because fewer companies supply sterile and ophthalmic lines. They need more careful handling and more working capital per order, so they complement, rather than replace, high-turn tablets and syrups.
Why does a monopoly or single-territory right matter for profit?
A genuine single-party territory means you aren’t competing on price with another partner selling the same brands nearby. That protects your margin; overlapping rights usually force discounts that quietly shrink your return.
Author: Biozia Lifesciences Editorial Team — insights drawn from Biozia Lifesciences’ WHO-GMP & ISO-certified manufacturing and PCD franchise operations in India, led by 40+ years of industry experience. This article is general business information and not medical or legal advice. Figures are indicative; confirm exact terms before you commit.
Interested in a Biozia PCD Franchise?
Get monopoly rights, a wide product range and full marketing support in your territory.